| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM197907053010102 |
| P953 | full work available at URL | http://www.nejm.org/doi/pdf/10.1056/NEJM197907053010102 |
| P698 | PubMed publication ID | 449915 |
| P2093 | author name string | A. L. Notkins | |
| J. J. Hooks | |||
| H. M. Moutsopoulos | |||
| N. I. Stahl | |||
| J. L. Decker | |||
| S. A. Geis | |||
| P2860 | cites work | Texas Reports on Biology and Medicine | Q26808291 |
| Vesicular stomatitis virus plaque production in monolayer cultures with liquid overlay medium: description and adaptation to a one-day, human interferon-plaque | Q27489621 | ||
| Bulletin on the rheumatic diseases | Q27710130 | ||
| Interferon treatment of NZB mice: accelerated progression of autoimmune disease | Q34455710 | ||
| Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis | Q36340307 | ||
| Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis | Q39908590 | ||
| Modulation of immune responses in newborn and adult mice by interferon | Q40682839 | ||
| Detection of lymphotoxins in vivo. I. Specific identification of short-lived LT activity in the plasma of various human patients employing rabbit anti-human LT sera in vitro | Q40898102 | ||
| Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating, antiviral activity, and host responses to infection | Q40903609 | ||
| Time and dosoge dependence of immunoenhancement by murine type II interferon preparations | Q40964874 | ||
| Systemic lupus erythematosus. Contrasts and comparisons | Q41530759 | ||
| Progressive glomerulonephritis in mice treated with interferon preparations at birth | Q44402351 | ||
| On the varied biologic effects of interferon | Q44811211 | ||
| Lymphokines in the rheumatoid joint | Q66896255 | ||
| Herpes zoster in patients with systemic lupus erythematosus | Q67389210 | ||
| Prognostic indices in lupus nephritis | Q67440483 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| interferon gamma-1b | Q582356 | ||
| autoimmune disease | Q8084905 | ||
| P304 | page(s) | 5-8 | |
| P577 | publication date | 1979-07-01 | |
| 1979-07-05 | |||
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Immune Interferon in the Circulation of Patients with Autoimmune Disease | |
| P478 | volume | 301 |
| Q46055629 | A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). |
| Q34694711 | A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE. |
| Q36854313 | A compass that points to lupus: genetic studies on type I interferon pathway. |
| Q36997265 | A conspicuous role for B cells In Sjögren's syndrome |
| Q33762839 | A genomic approach to human autoimmune diseases |
| Q41539015 | A hypothesis on the possible role of interferon in the initiation of acute gouty arthritis attack |
| Q36090346 | A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients |
| Q42707351 | A novel type I IFN-producing cell subset in murine lupus |
| Q41923577 | A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family |
| Q52975959 | A pathogenetic role for IL-21 in primary Sjögren syndrome. |
| Q36549197 | A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients |
| Q92667638 | A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection |
| Q69718281 | A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients |
| Q45833257 | A sensitive radioimmunoassay for circulating alpha-interferon in the plasma of healthy children and patients with measles virus infection |
| Q38557856 | A whole blood monokine-based reporter assay provides a sensitive and robust measurement of the antigen-specific T cell response. |
| Q67543231 | Absence of circulating interferon in patients with inflammatory bowel disease. Suggestion against an autoimmune etiology |
| Q33621871 | Absence of immunoreactive interferon-alpha in CSF from patients with multiple sclerosis |
| Q34103317 | Activation of the alternative NFκB pathway improves disease symptoms in a model of Sjogren's syndrome |
| Q37776830 | Activation of the type I interferon pathway in primary Sjogren’s syndrome |
| Q34240254 | Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes |
| Q38121787 | Advances in understanding the pathogenesis of primary Sjögren's syndrome |
| Q37388328 | Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. |
| Q34479620 | Aicardi-Goutières syndrome and the type I interferonopathies |
| Q80002715 | Altered editing in RNA editing adenosine deaminase ADAR2 gene transcripts of systemic lupus erythematosus T lymphocytes |
| Q37370498 | Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus |
| Q48128911 | An era of biological treatment in systemic lupus erythematosus. |
| Q34319930 | An etiopathogenic role for the type I IFN system in SLE. |
| Q37016308 | Animal models in autoimmune diseases: lessons learned from mouse models for Sjögren's syndrome |
| Q90312369 | Anticytokine Autoantibodies: Association with Infection and Immune Dysregulation |
| Q44225152 | Anticytokine therapy--new approach to the treatment of autoimmune and cytokine-disturbance diseases |
| Q40529769 | Antiphospholipid syndrome: from the laboratory bench to the patients' bedside |
| Q40100907 | Antiviral agents: An update—Part 2 |
| Q89266529 | Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus |
| Q47875729 | Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study |
| Q64998141 | Assay of an interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases |
| Q35147055 | Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. |
| Q37052138 | Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients |
| Q37331753 | Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept |
| Q51724948 | Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE. |
| Q35772872 | Autoimmunity through cytokine-induced dendritic cell activation |
| Q33562175 | B cell lymphokines in human systemic lupus erythematosus |
| Q36096756 | Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells |
| Q38425831 | Biologic therapies in systemic lupus erythematosus |
| Q40630439 | Biological activities of hematopoietic growth factors that lead to future clinical application |
| Q37638789 | Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosis |
| Q35810911 | Biomarkers for kidney involvement in pediatric lupus |
| Q37994309 | Biomarkers for systemic lupus erythematosus |
| Q37058781 | Biomarkers in systemic lupus erythematosus: challenges and prospects for the future |
| Q34213069 | Biosynthetic human interferon treatment of herpetic keratitis |
| Q35614331 | Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases |
| Q42234851 | Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells |
| Q35192862 | C1q-mediated repression of human monocytes is regulated by leukocyte-associated Ig-like receptor 1 (LAIR-1). |
| Q35082621 | Cell-specific type I IFN signatures in autoimmunity and viral infection: what makes the difference? |
| Q55100613 | Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. |
| Q45798603 | Characteristics of spontaneously produced and of virus-induced human LuKII cell interferons |
| Q34380241 | Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli |
| Q45805303 | Chronic production of interferon in carrier mice congenitally infected with lymphocytic choriomeningitis virus |
| Q69996773 | Circulating activated (DR-positive) T lymphocytes in a patient with autoeczematization |
| Q70340830 | Clearing of subacute cutaneous lupus erythematosus around molluscum contagiosum lesions |
| Q35743904 | Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus |
| Q45160212 | Clinical application of recombinant erythropoietin in the anemia of chronic disease. |
| Q60921469 | Clinical features of Sjögren's syndrome patients with autoantibodies against interferons |
| Q31080044 | Constitutive phosphorylation of interferon receptor A-associated signaling proteins in systemic lupus erythematosus |
| Q28080920 | Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus |
| Q55361040 | Conventional DCs from Male and Female Lupus-Prone B6.NZM Sle1/Sle2/Sle3 Mice Express an IFN Signature and Have a Higher Immunometabolism That Are Enhanced by Estrogen. |
| Q24556513 | Cross-regulation of TNF and IFN-alpha in autoimmune diseases |
| Q33565957 | Crosstalk Between Apoptosis and Autophagy: Environmental Genotoxins, Infection, and Innate Immunity |
| Q26741266 | Current and emerging treatment options in the management of lupus |
| Q36632600 | Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies |
| Q45020306 | Cutting Edge: Plasmacytoid Dendritic Cells in Late-Stage Lupus Mice Defective in Producing IFN-α. |
| Q44889767 | Cytokine expression in labial salivary glands from patients with primary Sjögren's syndrome |
| Q41605585 | Cytokines in autoimmune disease. |
| Q36659210 | Cytokines in systemic lupus erythematosus |
| Q37805978 | Cytokines in the pathophysiology of systemic lupus erythematosus |
| Q51397327 | DUSP23 is over-expressed and linked to the expression of DNMTs in CD4+ T cells from systemic lupus erythematosus patients. |
| Q37396863 | Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease |
| Q36699918 | Dendritic cells and cytokines in human inflammatory and autoimmune diseases |
| Q36908788 | Dendritic cells and the immunopathogenesis of systemic lupus erythematosus |
| Q33941433 | Dendritic cells in systemic lupus erythematosus |
| Q33860794 | Dermatomyositis after interferon alpha treatment |
| Q36439503 | Detection of gamma interferon in the sera of patients with Behçet's disease |
| Q40237578 | Detection of interferon alpha protein reveals differential levels and cellular sources in disease. |
| Q72717086 | Detection of interferon in the sera of patients with psoriasis, and its enhancement by PUVA treatment |
| Q89472291 | Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α |
| Q34177087 | Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus |
| Q52594390 | Development of a Validated Interferon Score Using NanoString Technology. |
| Q49966463 | Diagnostic and prognostic tests in systemic lupus erythematosus |
| Q88135099 | Differential gene expression analysis in CCLE lesions provides new insights regarding the genetics basis of skin vs. systemic disease |
| Q24796731 | Direct Toll-like receptor 2 mediated co-stimulation of T cells in the mouse system as a basis for chronic inflammatory joint disease |
| Q36370588 | Directing autoimmunity to nucleoprotein particles: the impact of dendritic cells and interferon alpha in lupus |
| Q41580653 | Dissecting the immune cell mayhem that drives lupus pathogenesis |
| Q37899957 | Disturbance of cytokine networks in Sjögren's syndrome |
| Q26773124 | Disturbed T Cell Signaling and Altered Th17 and Regulatory T Cell Subsets in the Pathogenesis of Systemic Lupus Erythematosus |
| Q92538507 | Docosahexaenoic Acid Consumption Impedes Early Interferon- and Chemokine-Related Gene Expression While Suppressing Silica-Triggered Flaring of Murine Lupus |
| Q33637487 | Dosage of X-linked Toll-like receptor 8 determines gender differences in the development of systemic lupus erythematosus |
| Q37690732 | Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study |
| Q54295685 | Editorial: "Interfering" with preeclampsia. |
| Q34161393 | Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort |
| Q70061367 | Effects of an anti-tumor polysaccharide, schizophyllan, on interferon-gamma and interleukin 2 production by peripheral blood mononuclear cells |
| Q41134740 | Effects of immunosuppression on herpes simplex virus growth in lymphocytes of patients with connective tissue diseases |
| Q80343465 | Elevated levels of endogenous apoptotic DNA and IFN-alpha in complement C4-deficient mice: implications for induction of systemic lupus erythematosus |
| Q37229729 | Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. |
| Q47193342 | Elevated serum levels of IL-6 and CXCL9 in autoimmune retinopathy (AIR) patients |
| Q30828464 | Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus |
| Q37729176 | Emerging biotherapies for Sjögren's syndrome |
| Q37813704 | Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity |
| Q28265144 | Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha |
| Q72678341 | Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis |
| Q42668884 | Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus |
| Q35816089 | Enhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritis |
| Q69219451 | Enhanced interferon-gamma (IFN) production by lymph node cells from autoimmune (MRL/1, MRL/n) mice |
| Q36901827 | Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus |
| Q72622172 | Enhancement of IgE-mediated histamine release from human basophils by immune-specific lymphokines |
| Q36995850 | Enhancement of basophil chemotaxis in vitro by virus-induced interferon |
| Q40621218 | Essential Requirement for IFN Regulatory Factor 7 in Autoantibody Production but Not Development of Nephritis in Murine Lupus. |
| Q72123678 | Eular Workshop on Rheumatology Research. Noordwijkerhout, February 19 82. Abstracts |
| Q43221507 | Evidence against an autoimmune aetiology for inflammatory bowel diseases |
| Q39169139 | Expanding the B Cell-Centric View of Systemic Lupus Erythematosus |
| Q37625812 | Expression of an anti-RNA autoantibody in a mouse model of SLE increases neutrophil and monocyte numbers as well as IFN-I expression |
| Q38203806 | Expression of the genes of interferons and other cytokines in normal and diseased tissues of man. |
| Q51524101 | Expression of type III interferons (IFNλs) and their receptor in Sjögren's syndrome. |
| Q41132062 | Fate of herpes simplex virus in lymphocytes from blood and joint effusions of systemic and pauciarticular juvenile chronic arthritis |
| Q36033680 | Female Bias in Systemic Lupus Erythematosus is Associated with the Differential Expression of X-Linked Toll-Like Receptor 8 |
| Q57062603 | Female predisposition to TLR7-driven autoimmunity: gene dosage and the escape from X chromosome inactivation |
| Q37416120 | Fueling autoimmunity: type I interferon in autoimmune diseases. |
| Q37097706 | Functions of human neutrophilic granulocytes after in vivo exposure to interferon alpha |
| Q63976610 | Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus |
| Q47422803 | Gene expression of cytokines (TNF-α, IFN-γ), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus |
| Q36560799 | Gene expression studies in systemic lupus erythematosus |
| Q28287170 | Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis |
| Q67826212 | Genes for Interleukin-1, Interleukin-6, and Tumor Necrosis Factor are Expressed at Markedly Reduced Levels in the Livers of Patients with Severe Liver Disease |
| Q35008001 | Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus. |
| Q38972234 | Genetic association and interaction between the IRF5 and TYK2 genes and systemic lupus erythematosus in the Han Chinese population |
| Q34350182 | Genetic associations in type I interferon related pathways with autoimmunity |
| Q37606651 | Genetic manipulation of the ApoF/Stat2 locus supports an important role for type I interferon signaling in atherosclerosis. |
| Q33682879 | Genetic regulation of serum cytokines in systemic lupus erythematosus |
| Q37332754 | Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies |
| Q35542816 | Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus |
| Q33703923 | Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients |
| Q37030643 | Genetics of clinical expression in SLE. |
| Q37450879 | Genetics of the type I interferon pathway in systemic lupus erythematosus |
| Q86117481 | Genome-wide transcriptional profiling of chronic cutaneous lupus erythematosus (CCLE) peripheral blood identifies systemic alterations relevant to the skin manifestation |
| Q38298730 | Genomic view of IFN-alpha response in pre-autoimmune NZB/W and MRL/lpr mice |
| Q82689901 | Genomic view of systemic autoimmunity in MRLlpr mice |
| Q43594987 | Gougerot-Sjögren syndrome. Revision of a problem... |
| Q41075749 | Heat shock protein 90 associates with Toll-like receptors 7/9 and mediates self-nucleic acid recognition in SLE. |
| Q51876600 | Herpes-varicella-zoster. |
| Q34526821 | How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end. |
| Q37211247 | How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets |
| Q34533285 | Human B lymphoma cell line producing B cell growth factor |
| Q45837952 | Human T-cell leukemia/lymphoma virus I and/or Epstein-Barr virus-infected B-cell lines spontaneously produce acid-labile alpha-interferon |
| Q38561058 | Human dendritic cell subsets and function in health and disease |
| Q33907781 | Human fibroblast interferon in tears of patients with picornavirus epidemic conjunctivitis |
| Q40473942 | Humoral markers of active Epstein-Barr virus infection associate with anti-extractable nuclear antigen autoantibodies and plasma galectin-3 binding protein in systemic lupus erythematosus. |
| Q37125180 | IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model |
| Q44911567 | IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus |
| Q36745302 | IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice |
| Q28253129 | IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus |
| Q36494607 | IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice |
| Q26795372 | Identification of Candidate Predictors of Lupus Flare |
| Q38159441 | Idiopathic fibrosing alveolitis: a review with emphasis on ultrastructural and immunohistochemical features |
| Q37699812 | Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus. |
| Q72542109 | Immune interferon does not stimulate formation of alpha and beta interferon induced human lupus-type inclusions |
| Q33554836 | Immune interferon in serum and synovial fluid in rheumatoid arthritis and related disorders |
| Q37676962 | Immune regulation in the retina |
| Q36236807 | Immunogenetics of systemic lupus erythematosus: A comprehensive review |
| Q72384546 | Immunologic profiles of adults with congenital bleeding disorders |
| Q46605746 | Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines |
| Q91847805 | Immunological pathogenesis and treatment of systemic lupus erythematosus |
| Q34460045 | Immunopathology of the noninfectious posterior and intermediate uveitides |
| Q42278404 | Immunoreactive IFN-gamma in CSF in neurological disorders |
| Q41145946 | Immunoregulatory effects of alpha-interferon. Effects on in-vitro antibody synthesis by lymphocytes from patients with rheumatoid arthritis |
| Q53830010 | Immunoregulatory effects of interferon-alpha. I. Interferon-alpha inhibits in vitro antibody synthesis by normal human lymphocytes. |
| Q37950925 | Impaired clearance of apoptotic cells in germinal centers: implications for loss of B cell tolerance and induction of autoimmunity |
| Q72724826 | Increased 2′,5′-oligoadenylate synthetase activity in blood mononuclear leukocytes from patients with advanced cutaneous T-cell lymphoma |
| Q48102522 | Increased Abundance of Plasmacytoid Dendritic Cells and Interferon-Alpha Induces Plasma Cell Differentiation in Patients of IgA Nephropathy |
| Q36492750 | Increased activation of toll-like receptors-7 and -8 of peripheral blood mononuclear cells and upregulated serum cytokines in patients with pediatric systemic lupus erythematosus |
| Q67487272 | Induction of Tubuloreticular Structures in Cultured Human Endothelial Cells by Recombinant Interferon Alfa and Beta |
| Q54774147 | Induction of an atypical interferon by bacteroides fragilis and Escherichia coli in experimental infections and in leukocyte cultures. |
| Q37351980 | Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. |
| Q35675529 | Induction of clinical autoimmune disease by therapeutic interferon-alpha |
| Q45054059 | Induction of cylindrical confronting cisternae (AIDS inclusions) in Daudi lymphoblastoid cells by recombinant alpha-interferon |
| Q41355698 | Influence of alpha-interferon therapy on blood lymphoid cells. Studies on antibody production, mixed lymphocyte culture response, mitogen responsiveness and 2'-5'oligoadenylate synthetase activity |
| Q67728509 | Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon |
| Q35675526 | Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor |
| Q33688996 | Inhibition of lysophosphatidic acid receptor ameliorates Sjögren's syndrome in NOD mice. |
| Q41140498 | Inhibition of natural killer cell activity by serum from patients with systemic lupus erythematosus: roles of disease activity and serum interferon |
| Q64113375 | Innate Immune Cells' Contribution to Systemic Lupus Erythematosus |
| Q36172913 | Innate pathways to B-cell activation and tolerance |
| Q72669967 | Insensitivity to interferon of NK cells from patients with systemic lupus erythematosus |
| Q72680073 | Interferon Production, Cellular and Humoral Immunity in Splenectomized Patients |
| Q72742194 | Interferon activity and its characterization in the sera of patients with head and neck cancer |
| Q45211051 | Interferon activity and its characterization in the sera of patients with premalignant lesions arising in oral mucosa. |
| Q34790180 | Interferon alpha (IFNalpha) and psychiatric syndromes: a review |
| Q35603587 | Interferon alpha as a primary pathogenic factor in human lupus |
| Q30410652 | Interferon alpha on NZM2328.Lc1R27: enhancing autoimmunity and immune complex-mediated glomerulonephritis without end stage renal failure |
| Q28282720 | Interferon alpha-induced lupus: proof of principle |
| Q72686419 | Interferon and natural killer cells in systemic lupus erythematosus |
| Q36089833 | Interferon as a cause of endoplasmic reticulum abnormalities within hepatocytes in newborn mice |
| Q70404927 | Interferon gamma production by human intestinal mucosal mononuclear cells. Decreased levels in inflammatory bowel disease |
| Q72691591 | Interferon in suction blister fluid from psoriatic lesions |
| Q34641073 | Interferon messenger RNA is produced constitutively in the organs of normal individuals |
| Q36319618 | Interferon pathway activation in systemic lupus erythematosus |
| Q93188187 | Interferon pathway in SLE: one key to unlocking the mystery of the disease |
| Q72662602 | Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis |
| Q35125991 | Interferon regulatory factor 1 marks activated genes and can induce target gene expression in systemic lupus erythematosus |
| Q35784689 | Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons |
| Q38123907 | Interferon regulatory factor 5 and autoimmune lupus. |
| Q43538775 | Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice. |
| Q34988497 | Interferon regulatory factors in human lupus pathogenesis |
| Q35014051 | Interferon regulatory factors: critical mediators of human lupus |
| Q70447972 | Interferon system in patients with systemic juvenile chronic arthritis: in vivo and in vitro studies |
| Q91345396 | Interferon target-gene expression and epigenomic signatures in health and disease |
| Q40111806 | Interferon triggers experimental synovitis and may potentiate auto-immune disease in humans |
| Q90613547 | Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis |
| Q33744320 | Interferon-alpha: a therapeutic target in systemic lupus erythematosus |
| Q39845994 | Interferon-gamma induces the expression of H-2 and Ia antigens on brain cells |
| Q70493187 | Interferon-gamma production by peripheral blood mononuclear cells from patients with Behçet's syndrome |
| Q36347970 | Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon |
| Q39517523 | Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells? |
| Q62111834 | Interferon-γ polymorphisms in systemic lupus erythematosus |
| Q40108361 | Interferons with Special Emphasis on the Immune System |
| Q40075831 | Interferons, a group of multiple lymphokines |
| Q40109995 | Interferon—Present and Future Prospects |
| Q24797820 | Interpreting interest in interferon-alpha |
| Q53261581 | Investigation of the HIN200 locus in UK SLE families identifies novel copy number variants. |
| Q26775756 | Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications |
| Q42140639 | Leukoregulin, a novel cytokine enhances the anti-herpesvirus actions of acyclovir |
| Q84112335 | Linking interferon regulatory factors to the pathogenesis of human lupus |
| Q30873883 | Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus |
| Q91650487 | Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus |
| Q47875908 | Lupus-Associated Functional Polymorphism in PNP Causes Cell Cycle Abnormalities and Interferon Pathway Activation in Human Immune Cells. |
| Q41539333 | Lymphocyte abnormalities in Behçet's syndrome |
| Q41156847 | Lymphocytes bearing Fc gamma receptors in rheumatoid arthritis. IV. Increased numbers and activation of Facb-R+ cells after immunisation of healthy individuals |
| Q72717053 | Lymphopenia in systemic lupus erythematosus: possible role of interferon |
| Q35996076 | Male sterility of transgenic mice carrying exogenous mouse interferon-beta gene under the control of the metallothionein enhancer-promoter |
| Q35809392 | Mechanisms of deficient type I protein kinase A activity in lupus T lymphocytes |
| Q70288866 | Mechanisms of macrophage activation in rheumatoid arthritis: the role of gamma-interferon |
| Q36905584 | Mechanistic biomarkers for clinical decision making in rheumatic diseases |
| Q33790174 | Mediation of nonerosive arthritis in a mouse model of lupus by interferon-alpha-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. |
| Q40105409 | Mediators of cellular immune reactions |
| Q35499383 | Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus |
| Q24795089 | Microarray analysis of gene expression in lupus |
| Q35675519 | Microarray analysis of interferon-regulated genes in SLE. |
| Q37734746 | Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease |
| Q33636927 | Minireview: Glucocorticoids in autoimmunity: unexpected targets and mechanisms |
| Q70404929 | Modulation of intestinal immune reactivity by interleukin 2. Phenotypic and functional analysis of lymphokine-activated killer cells from human intestinal mucosa |
| Q54512807 | Modulation of polyclonal B cell differentiation by human leucocyte alpha interferon. |
| Q35503086 | Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells |
| Q37660278 | Molecular insights into systemic lupus erythematosus pathogenesis |
| Q34027485 | Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus |
| Q72664584 | Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis |
| Q35701721 | Multiple organ failure. Pathophysiology and potential future therapy |
| Q34090517 | Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop |
| Q36054583 | Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset |
| Q71219495 | Natural killer cell activity in inflammatory joint disease |
| Q23916824 | Natural killer cell tumoricidal activity in cigarette smokers and in silicotics |
| Q34614312 | Natural killer cells are present in the normal human lung but are functionally impotent |
| Q38670752 | Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application |
| Q28301151 | Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus |
| Q35090145 | Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases |
| Q37306015 | Neutrophil Extracellular Traps and Systemic Lupus Erythematosus |
| Q37535318 | Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. |
| Q33671295 | New roles for the major human 3'-5' exonuclease TREX1 in human disease |
| Q37819256 | Nucleic acid sensing Toll-like receptors in autoimmunity |
| Q34017633 | Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus |
| Q36403653 | Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus |
| Q37117336 | Oral manifestations of Sjögren's syndrome |
| Q37038484 | Pathophysiology of cutaneous lupus erythematosus |
| Q72732468 | Periodicity of interferon appearance in serum of patients with systemic lupus erythematosus |
| Q86431603 | Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody |
| Q38771936 | Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus |
| Q36583115 | Phenotypic and functional alterations of pDCs in lupus-prone mice. |
| Q33956662 | Pivotal Functions of Plasmacytoid Dendritic Cells in Systemic Autoimmune Pathogenesis |
| Q34583337 | Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus |
| Q37730992 | Potential role of IFNα in adult lupus |
| Q36378535 | Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases |
| Q44115820 | Preferential activation of helper/inducer T lymphocytes in autoimmune chronic active hepatitis |
| Q37549027 | Premature vascular damage in systemic lupus erythematosus: an imbalance of damage and repair? |
| Q72381468 | Preparation and Characterization of Monoclonal Antibodies Directed at Epitopes of Human IFN-γ |
| Q68103913 | Presence of interferon and anti-interferon in patients with systemic lupus erythematosus |
| Q44448575 | Production and role of interferon in physiological conditions |
| Q42291845 | Progression of type 1 diabetes from the prediabetic stage is controlled by interferon-α signaling |
| Q43719366 | Promoter polymorphisms in the IRF3 gene confer protection against systemic lupus erythematosus |
| Q34022033 | Promoter variant of PIK3C3 is associated with autoimmunity against Ro and Sm epitopes in African-American lupus patients |
| Q37830007 | Proteome analysis of biological fluids from autoimmune-rheumatological disorders |
| Q37328661 | Rapid, quantitative, semiautomated assay for virus-induced and immune human interferons |
| Q37902251 | Recent advances in cytokines in cutaneous and systemic lupus erythematosus |
| Q33964547 | Recent advances in the genetics of systemic lupus erythematosus |
| Q73338053 | Recurrent aphthous stomatitis |
| Q36727307 | Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors |
| Q38042201 | Regulation of the innate immune system by ubiquitin and ubiquitin-like modifiers |
| Q38306720 | Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus |
| Q37104465 | Renal deposition of alpha interferon in systemic lupus erythematosus |
| Q37587370 | SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome |
| Q34796327 | SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature |
| Q45943683 | Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. |
| Q54677630 | Serum Levels of Interferon-gamma, Cytotoxic Factor and Soluble Interleukin-2 Receptor in Childhood Hemophagocytic Syndromes. |
| Q33555685 | Serum alpha interferon and lymphocyte inclusions in systemic lupus erythematosus |
| Q69831888 | Serum interferon activity in inflammatory bowel disease. Arachidonic acid release and lipoxygenation activated by alpha-class interferon in human neutrophils |
| Q72689915 | Serum interferon in Navajo children with severe combined immunodeficiency disease inhibits lymphoblastogenesis |
| Q36134344 | Serum interferon levels and natural killer cell activity in patients with asbestosis |
| Q72664589 | Serum interferon levels in patients with systemic lupus erythematosus |
| Q69018287 | Serum levels of interferons in patients with systemic lupus erythematosus |
| Q37435264 | Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling |
| Q36343862 | Severity of lymphocytic choriomeningitis virus disease in different strains of suckling mice correlates with increasing amounts of endogenous interferon |
| Q28080459 | Sexual dimorphism in autoimmunity |
| Q36603706 | Should we inhibit type I interferons in sepsis? |
| Q36067728 | Siglec-H protects from virus-triggered severe systemic autoimmunity |
| Q92876039 | Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus |
| Q69972398 | Spontaneous lymphocyte activity in rheumatoid arthritis in a longitudinal study in relation to gold therapy |
| Q33478257 | Spontaneous production of human gamma interferon in vitro by splenic lymphocytes of patients with idiopathic thrombocytopenic purpura |
| Q92696119 | Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date |
| Q69880024 | Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus |
| Q40076563 | Substrates for Phagocytes in Joints |
| Q92800200 | Systemic Lupus Erythematosus and DNA Degradation and Elimination Defects |
| Q38534457 | Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System. |
| Q39053118 | Systemic lupus erythematosus biomarkers: the challenging quest |
| Q36915688 | Systemic lupus erythematosus in children: current and emerging therapies |
| Q40842099 | Systemic lupus erythematosus — A state of hyperinterferonemia? |
| Q40090535 | Systemic lupus erythematosus: 25 years of treatment related to immunopathology. |
| Q36673286 | Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. |
| Q40653713 | T cell subsets in glomerular diseases |
| Q35860040 | T-lymphocyte signalling in systemic lupus erythematosus: a lipid raft perspective |
| Q33354714 | TLRs and IFNs: critical pieces of the autoimmunity puzzle |
| Q36423215 | Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. |
| Q35824498 | Targeting interferon-alpha: a promising approach for systemic lupus erythematosus therapy. |
| Q38458846 | Targeting interferons in systemic lupus erythematosus: current and future prospects |
| Q24299196 | The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression |
| Q37052133 | The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus |
| Q90613288 | The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus |
| Q47134266 | The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases |
| Q54983754 | The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE. |
| Q34779998 | The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases |
| Q38085206 | The applied basic research of systemic lupus erythematosus based on the biological omics. |
| Q40208976 | The clinical implications of human interferon. |
| Q35294513 | The dysregulation of cytokine networks in systemic lupus erythematosus |
| Q92826945 | The immune cell landscape in kidneys of patients with lupus nephritis |
| Q104459120 | The long non-coding RNA LUCAT1 is a negative feedback regulator of interferon responses in humans |
| Q70425853 | The occurrence of cancer in immune deficiencies |
| Q90575861 | The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus |
| Q41540639 | The possible participation of interferon inhibitor in the formation of the remission in autoimmune diseases and allergy (hypersensitivity of immediate type) |
| Q38211414 | The potential role of interferons and interferon antagonists in inflammatory disease |
| Q35294438 | The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus |
| Q89181533 | The role of neutrophil extracellular traps in rheumatic diseases |
| Q36898668 | The role of type I interferons in TLR responses. |
| Q37308042 | The search for lupus biomarkers |
| Q53341131 | The type I IFN system in rheumatoid arthritis. |
| Q39672500 | The type I interferon signaling pathway is a target for glucocorticoid inhibition. |
| Q35514368 | The type I interferon system in the etiopathogenesis of autoimmune diseases |
| Q33939981 | The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies |
| Q34106220 | Therapeutic Strategies for SLE Involving Cytokines: Mechanism-Oriented Therapies Especially IFN- Targeting Gene Therapy |
| Q38059809 | Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling. |
| Q69381954 | Therapeutic effect of human fibroblast interferon on premalignant lesions arising in oral mucosa. A pilot study |
| Q36811131 | Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists |
| Q34731092 | Therapy of systemic lupus erythematosus: a look into the future |
| Q87514118 | Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway |
| Q35153786 | Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c⁺ B-cell population is important for the development of autoimmunity |
| Q34153062 | Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. |
| Q44146953 | Transcript mutations of the alpha regulatory subunit of protein kinase A and up-regulation of the RNA-editing gene transcript in lupus T lymphocytes |
| Q71437949 | Transplant approach establishes that kidneys are responsible for serum CSF-1 but require a stimulus in MRL-lpr mice |
| Q72653725 | Treatment Of NZB/NZW F1 Hybrid Mice withMycobacterium Bovis Strain BCG or Type II Interferon Preparations Accelerates Autoimmune Disease |
| Q79946741 | Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms |
| Q35456519 | Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies |
| Q36504624 | Treatment targets in systemic lupus erythematosus: biology and clinical perspective |
| Q72679590 | Tuboreticular structures in Kaposi's sarcoma |
| Q34350190 | Type 1 interferons and myositis |
| Q38335622 | Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine. |
| Q38840206 | Type I Interferon Inhibition of MicroRNA-146a Maturation Through Up-Regulation of Monocyte Chemotactic Protein-Induced Protein 1 in Systemic Lupus Erythematosus |
| Q35675508 | Type I interferon and autoimmune disease |
| Q35549980 | Type I interferon and systemic lupus erythematosus |
| Q38867891 | Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options |
| Q35555038 | Type I interferon correlates with serological and clinical manifestations of SLE |
| Q37838003 | Type I interferon in organ-targeted autoimmune and inflammatory diseases |
| Q33852174 | Type I interferon in the pathogenesis of lupus |
| Q47108722 | Type I interferon-mediated autoinflammation due to DNase II deficiency |
| Q36072422 | Type I interferons (alpha/beta) in immunity and autoimmunity |
| Q37666513 | Type I interferons: crucial participants in disease amplification in autoimmunity |
| Q39716482 | Ultrastructural features and prevalence of tubuloreticular structures in the ocular vasculature of patients with AIDS: a study of 23 cases |
| Q38988559 | Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics |
| Q70318630 | Unique properties of auranofin as a potential anti-rheumatic drug |
| Q38166691 | Virus-related pathology: is the continued presence of the virus necessary? |
| Q40097955 | What's new. |
| Q72727201 | β2m levels, autoimmune diseases, and interferon |
Search more.